icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
Voir aussi
Décision d'accès précoce
22/12/2022
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
DLtLLHX3LVZrbUqh